Adaptive Biotechnologies Q2 MRD revenue up 36% YoY; updates FY guidance

Adaptive Biotechnologies Corp

2024-Q2 EPS reported -$0.64 revenue$85,063,000

Total Q2 revenue $43.2M (-12% YoY); MRD revenue $35.3M (+36%), Immune Medicine $7.9M (-66%).
Net loss $46.2M vs $47.8M YoY; Adjusted EBITDA loss $21.4M vs $24.8M.
clonoSEQ test volume 18,520 (+36% YoY); recognized $3.0M MRD regulatory milestone.
FY 2024 MRD revenue guidance raised to $140-145M (from $135-140M); total OPEX guidance lowered to $340-350M.
Cash and securities $291.9M as of June 30.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.